These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31014100)

  • 1. Insulin resistance: Impact on therapeutic developments in diabetes.
    Bailey CJ
    Diab Vasc Dis Res; 2019 Mar; 16(2):128-132. PubMed ID: 31014100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 4. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.
    Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
    Prim Care Diabetes; 2019 Jun; 13(3):221-232. PubMed ID: 30573348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME; Kosiborod M
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2019 Feb; 18(1):19. PubMed ID: 30819188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of Type 2 Diabetes: a Practical Approach].
    Donath M
    Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose lowering and the kidney: are all drug classes equal?
    Wong MG; Jardine M; Perkovic V
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
    [No Abstract]   [Full Text] [Related]  

  • 15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
    Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
    Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Add-on therapies to metformin for type 2 diabetes.
    Shomali M
    Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding treatment options for type 2 diabetes: the old and the new.
    Pratley RE
    Diabetes Educ; 2009; 35 Suppl 1():4S-11S. PubMed ID: 19218561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.